EP
AKRO

Essential Partners’s Akero Therapeutics AKRO Stock Holding History

Essential Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-138
Closed -$6.55K – 2777
2025
Q3 		$6.55K Buy
138
+133
+2,660% +$6.44K ﹤0.01% 1321
2025
Q2 		$267 Buy
+5
New +$227 ﹤0.01% 1871

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Essential Partners's AKRO Position: Q4 2025 in Review

Essential Partners sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 138 shares — an estimated $6.55K sold.

Essential Partners first reported a position in AKRO in Q2 2025 and held it in 2 quarters. The position peaked at $6.55K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Essential Partners reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Essential Partners sold 138 Akero Therapeutics shares in Q4 2025, an estimated $6.55K.
  • Essential Partners first reported a position in Akero Therapeutics in Q2 2025 and held it in 2 quarters.
  • Essential Partners's Akero Therapeutics position peaked at $6.55K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Essential Partners's 13F filing for Q4 2025, filed 21 May 2026.